{"nctId":"NCT02634580","briefTitle":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","startDateStruct":{"date":"2016-02-27","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":61,"armGroups":[{"label":"Ezetimibe (Q2W)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Evolocumab","Drug: Ezetimibe","Drug: Placebo to Evolocumab"]},{"label":"Ezetimibe (QM)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Evolocumab","Drug: Ezetimibe","Drug: Placebo to Evolocumab"]},{"label":"Evolocumab Q2W","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Placebo Ezetimibe"]},{"label":"Evolocumab QM","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Placebo Ezetimibe"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Ezetimibe","otherNames":["Zetia"]},{"name":"Placebo to Evolocumab","otherNames":[]},{"name":"Placebo Ezetimibe","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 20 to ≤ 80 years of age\n* Japanese by self-identification\n* Not on a statin or on a low dose statin with stable dose for at least 4 weeks.\n* Subject not at LDL-C goal\n* History of statin intolerance to at least 2 statins\n* Lipid lowering therapy has been stable prior to screening for at least 4 weeks\n* Fasting triglycerides ≤ 400 mg/dL\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) III or IV heart failure\n* Uncontrolled cardiac arrhythmia\n* Uncontrolled hypertension\n* Type 1 diabetes\n* Poorly controlled type 2 diabetes\n* Uncontrolled hypothyroidism or hyperthyroidism","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12","description":"For all efficacy endpoints the two dosing regimens (every 2 weeks and every month) for each treatment were pooled for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.39","spread":"3.19"},{"groupId":"OG001","value":"-59.75","spread":"2.30"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.13","spread":"3.45"},{"groupId":"OG001","value":"-59.27","spread":"2.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"6.6"},{"groupId":"OG001","value":"-113.2","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.4","spread":"7.0"},{"groupId":"OG001","value":"-112.7","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL","description":"Mean low density lipoprotein-cholesterol response was defined as LDL-C \\< 70 mg/dL \\[1.8 mol/L\\].","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"56.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a LDL-C of Less Than 70 mg/dL at Week 12","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"52.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.80","spread":"2.17"},{"groupId":"OG001","value":"-39.24","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.69","spread":"2.34"},{"groupId":"OG001","value":"-38.52","spread":"1.70"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.82","spread":"2.77"},{"groupId":"OG001","value":"-52.35","spread":"2.01"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.28","spread":"3.03"},{"groupId":"OG001","value":"-51.71","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.23","spread":"2.69"},{"groupId":"OG001","value":"-48.90","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.32","spread":"2.99"},{"groupId":"OG001","value":"-47.91","spread":"2.14"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.73","spread":"2.69"},{"groupId":"OG001","value":"-44.34","spread":"1.94"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.34","spread":"2.81"},{"groupId":"OG001","value":"-44.39","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.39","spread":"2.67"},{"groupId":"OG001","value":"-52.46","spread":"1.91"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.62","spread":"2.88"},{"groupId":"OG001","value":"-51.91","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.89","spread":"4.34"},{"groupId":"OG001","value":"-37.02","spread":"3.11"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.21","spread":"5.02"},{"groupId":"OG001","value":"-36.41","spread":"3.59"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.21","spread":"5.92"},{"groupId":"OG001","value":"-1.73","spread":"4.28"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.87","spread":"7.71"},{"groupId":"OG001","value":"1.92","spread":"5.60"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.10","spread":"2.50"},{"groupId":"OG001","value":"11.06","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"2.59"},{"groupId":"OG001","value":"12.04","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.67","spread":"5.89"},{"groupId":"OG001","value":"-5.34","spread":"4.25"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL-C at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.06","spread":"8.00"},{"groupId":"OG001","value":"-1.42","spread":"5.80"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":["Nasopharyngitis","Diarrhoea","Pharyngitis","Cough","Hypertension"]}}}